Denosumab in the treatment of osteoporosis associated with chronic kidney disease
- PMID: 38373426
- DOI: 10.1016/S2213-8587(24)00057-3
Denosumab in the treatment of osteoporosis associated with chronic kidney disease
Conflict of interest statement
AC receives consultancy fees from FMC, speaker fees from AstraZeneca and Boehringer Ingelheim, support for attending meetings from AstraZeneca, is a member of the European Dialysis Working Group of the European Renal Association, and is President of the Romanian Society of Nephrology. MA receives support for attending meetings from AstraZeneca.
Comment on
-
Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients.JAMA. 2024 Feb 13;331(6):491-499. doi: 10.1001/jama.2023.28239. JAMA. 2024. PMID: 38241060 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical